{'fraction_non_alphanumeric': 0.02372479240806643, 'fraction_numerical': 0.01542111506524318, 'mean_word_length': 5.0285714285714285, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of antihypertensive treatment on lipids and fibrinogen: Greek multicentre study of cilazapril.

The effect cilazapril (CLZ) treatment on serum lipids and fibrinogen was studied in 114 hypertensive patients for 18 weeks. Blood pressure, heart rate, lipid profile and fibrinogen were measured before and at the end of the study in all patients. Satisfactory blood pressure control was seen in 68% of the patients (group A) after 4 weeks of treatment with 5 mg CLZ monotherapy, while a single dose of chlorthalidone, 25 mg daily, was added to the therapeutic regimen of the remaining 32% of patients (group B) to achieve blood pressure control. We conclude that CLZ has a slight beneficial effect on the lipid profile and a significantly beneficial effect on fibrinogen, but its combination with a diuretic reverses this beneficial effect.